Worth reading
55In focus
Scored from 2 of 5 sectionsDirection
Neutral
Direction inferred from the company’s description.Scale
10000
SharesWording
Definitive
How definitive the wording is.Details of issuance or disposal
Series 9 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause)
発行・処分する株式数
Shares delivered during the month: 10,000 new shares; 0 treasury shares transferred
発行済株式総数
Exercise ratio subject to exercise restrictions: 0.02%
The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.
Terms of the stock acquisition rights
Exercise price
The exercise price during the target month ranged from ¥100 to ¥121. Details of the adjustment clause and the floor price: Not disclosed
Number of Stock Acquisition Rights
Total issued: 500,000 rights; unexercised as of the end of the month preceding the target month: 476,500 rights; unexercised as of the reporting date in the target month: 476,400 rights
Procedures under the Corporate Code of Conduct
The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations
Most recent equity financing
31 March 2026 issuance: Series 9 stock acquisition rights (with exercise price adjustment clause). Amount: Not disclosed
| Item | Details |
|---|---|
| Type of issuance or disposal | Series 9 stock acquisition rights issued through a third-party allotment (with exercise price adjustment clause) |
| Number of shares to be issued or disposed of | Shares delivered during the month: 10,000 new shares; 0 treasury shares transferred |
| Dilution Rate | Exercise ratio subject to exercise restrictions: 0.02% |
| Total number of issued shares | 45,874,400 shares (as of the end of the month preceding the target month) → Not disclosed |
| Exercise price | The exercise price during the target month ranged from ¥100 to ¥121. Details of the adjustment clause and the floor price: Not disclosed |
| Number of Stock Acquisition Rights | Total issued: 500,000 rights; unexercised as of the end of the month preceding the target month: 476,500 rights; unexercised as of the reporting date in the target month: 476,400 rights |
| Procedures under the Corporate Code of Conduct | The disclosure describes compliance with the exercise restrictions under Article 434 of the Listing Regulations |
| Most recent equity financing | 31 March 2026 issuance: Series 9 stock acquisition rights (with exercise price adjustment clause). Amount: Not disclosed |
Items this document does not state (20)
Issue price and disposal priceTotal issue valueAmount of funds to be raisedEstimated issuance expensesSpecific use of fundsPayment dateIntended allotteeIntended allottee's holding policyBasis for determining the amount to be paidExercise periodTransfer restriction periodConditions for lifting transfer restrictionsReason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split RatioMajor shareholders after the offeringImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The company does not state a reason.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.